Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3CNS 3Thoracic 2Myeloid 2Sarcoma 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 50Carcinoma, Non-Small-Cell Lung 26Squamous Cell Carcinoma of Head and Neck 25Head and Neck Neoplasms 12Neoplasm Metastasis 11Neoplasms 10Colonic Neoplasms 10Rectal Neoplasms 9Pancreatic Neoplasms 9Lung Neoplasms 9Mouth Neoplasms 6Carcinoma, Squamous Cell 6Carcinoma 6Laryngeal Neoplasms 5Hypopharyngeal Neoplasms 5Oropharyngeal Neoplasms 4Thyroid Neoplasms 3Solid Tumors 3Ovarian Neoplasms 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Pancreatic Ductal 3Breast Neoplasms 3Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Laryngeal Diseases 2mCRC 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 5Nivolumab 5selpercatinib 4Iodine-124 4Biopsy 4binimetinib 3Iodine-131 3Cetuximab 3ulixertinib 2trametinib 2pembrolizumab 2omipalisib 2larotrectinib 2defactinib 2dabrafenib 2Surveys and Questionnaires 2Sunitinib 2Radiosurgery 2Ipilimumab 2Immunoglobulin G 2Gemcitabine 2Disulfides 2Cyclophosphamide 2CTLA-4 Antigen 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tipifarnib 1temsirolimus 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Cetuximab × 90 days × Clear all
NCT05355701 2026-06-05

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pfizer

Phase 1 Recruiting
267 enrolled
CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡